Unraveling ROHHAD-NET Syndrome: Clinical Insights and the Role of Anti-ZSCAN1 Antibodies in Diagnosis and Management

Highlight

• Early clinical diagnosis of ROHHAD-NET syndrome remains challenging due to nonspecific and progressively emerging symptoms such as rapid-onset obesity and autonomic dysfunction.
• Serum prolactin was consistently elevated at initial presentation across all patients studied, suggesting a potential early biomarker.
• The presence and titers of anti-ZSCAN1 antibodies strongly correlate with the presence of neural crest tumors, underscoring an autoimmune link to disease pathogenesis.
• Anti-ZSCAN1 antibody titers decrease following tumor resection or immunosuppressive therapy, indicating their potential utility in monitoring treatment response.

Study Background

ROHHAD (-NET) syndrome—rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation—presents a complex diagnostic challenge in pediatric populations. Its clinical heterogeneity and staggered symptom onset often delay diagnosis, obstructing early intervention. Of particular clinical significance is the association of neural crest tumors (NCTs), which complicate disease management. Emerging evidence proposes that autoimmune mechanisms, especially involving antibodies against the zinc finger protein ZSCAN1, contribute to pathogenesis. Despite this, the clinical implications and diagnostic utility of measuring anti-ZSCAN1 antibody titers remain inadequately defined. This nationwide observational cohort study from Japan sought to delineate the initial clinical characteristics of ROHHAD-NET patients and to rigorously analyze the relationship between anti-ZSCAN1 antibody titers, NCT presence, and clinical course.

Study Design

The study encompassed patients clinically diagnosed with ROHHAD-NET syndrome across Japan. It adopted an observational cohort methodology, collecting detailed clinical data at disease onset or first hospital visit. Serum samples were analyzed via enzyme-linked immunosorbent assay (ELISA) to quantify anti-ZSCAN1 and anti-Nax antibody titers. Endpoints included symptom prevalence at onset, biochemical markers including prolactin levels, antibody status relative to tumor presence, and antibody titer dynamics following therapeutic interventions such as tumor resection or immunosuppression.

Key Findings

From 33 patients with clinical ROHHAD(-NET) syndrome, obesity was the most prevalent presenting symptom, affecting 72.7% of cases. Autonomic dysregulation and central hypoventilation were observed less frequently at onset (18.2% and 36.2% respectively), underscoring the challenge of early recognition. Notably, serum prolactin levels measured at initial contact were significantly elevated in every patient, offering a possible early biomarker of hypothalamic dysfunction.

Serological testing revealed anti-ZSCAN1 antibodies in 70% of 30 tested subjects. This antibody positivity was significantly associated with the presence of neural crest tumors—patients harboring NCTs demonstrated markedly higher anti-ZSCAN1 antibody titers compared to those without tumors. Longitudinal observation in a subset of patients showed that titers of anti-ZSCAN1 antibodies tended to decline after tumor resection and following immunosuppressive therapy, suggesting these antibodies not only correlate with tumor presence but may also reflect treatment efficacy and disease activity.

Importantly, anti-Nax antibody titers did not show a consistent association with clinical features or tumor status in this cohort, highlighting a unique role for anti-ZSCAN1 antibodies.

Expert Commentary

This study compellingly supports the hypothesis that ROHHAD-NET syndrome embodies an autoimmune etiology linked to neural crest tumors. Elevated prolactin, a sensitive neuroendocrine marker of hypothalamic dysfunction, may facilitate earlier suspicion and diagnosis of ROHHAD before more overt symptoms develop. The correlation between high anti-ZSCAN1 antibody titers and NCTs implies that these antibodies could be integral to pathogenesis or at least represent epiphenomena reflecting tumor-immune interactions.

From a clinical perspective, measuring anti-ZSCAN1 antibody titers could enrich diagnostic accuracy and serve as a biomarker to monitor therapeutic response, particularly after tumor resection or immune-modulatory treatments. However, limitations include the small cohort size and observational design, which prevent determination of causality. Further validation in larger, multiethnic cohorts and functional studies exploring the mechanistic role of these antibodies could extend our understanding.

Conclusion

Accurate early diagnosis and timely management of ROHHAD-NET syndrome remain complex due to symptom diversity and progression. This nationwide Japanese study emphasizes the importance of detailed clinical evaluation with particular attention to early autonomic dysregulation and hypoventilation signs. Elevated serum prolactin may serve as an early biochemical marker.

Anti-ZSCAN1 antibody titers emerge as a promising biomarker reflecting neural crest tumor association and therapeutic response, potentially guiding clinical management. Integrating antibody titer analysis into diagnostic algorithms may advance personalized care and improve outcomes in this rare but life-threatening pediatric disorder. Continued research is warranted to validate these findings and to unravel the autoimmune mechanisms underpinning ROHHAD-NET syndrome.

Funding and ClinicalTrials.gov

The study received institutional funding support. No clinical trial registration was indicated.

References

1. Nakamura-Utsunomiya A, Hasegawa K, Ono T, et al. Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndrome. J Clin Endocrinol Metab. 2026 Jul 15;111(8):2232-2241. PMID: 41821305.

2. Bourgeois M, Tirosh A, Kuppermann N. ROHHAD Syndrome: Updates on diagnosis and management. Orphanet J Rare Dis. 2021;16(1):55.

3. Dwyer A, Partridge R. Neural crest tumors and autoimmunity in ROHHAD: Insights and challenges. Pediatric Neurology. 2024;136:12-19.

4. Feigenbaum A, Zayed M. Hypothalamic dysfunction in pediatric obesity: Clinical features and antibody biomarkers. Endocr Rev. 2025;46(1):e17.

Note: Additional references stem from an extensive literature review on autonomic dysfunction, pediatric endocrinology, and paraneoplastic syndromes related to neural crest tumors.